From €66.00 €56.10
MLN9708 is a prodrug form of the proteasome inhibitor MLN2238 (Item No. 18385).{31628,31627} It is converted to MLN2238 via hydrolysis in the plasma.{31628} MLN9708 inhibits the 20S proteasome (IC50 = 8.4 nM for the human enzyme) and binds to caseinolytic protease P (Kd = 7,300 nM for the S. aureus enzyme).{57957,58924} It inhibits the proliferation of RPMI-8226, U266B, and ARH-77 multiple myeloma cells with IC50 values of 49.4, 67, and 43.5 nM, respectively.{57957}
Territorial Availability: Available through Bertin Technologies only in France
| Size | 1 mg, 10 mg, 5 mg, 50 mg |
|---|---|
| Shipping | dry ice |
| CAS number | 1201902-80-8 |
| Molecular formula | C20H23BCl2N2O9 |
| Smiles | ClC1=C(C(NCC(N[C@@H](CC(C)C)B2OC(CC(O)=O)(C(O)=O)CC(O2)=O)=O)=O)C=C(Cl)C=C1 |
| Molecular weight | 517,1 |
| Custom code | 2922.19 |
| Formulation | A crystalline solid |
| Purity | ≥95% |
| UNSPSC code | 12352100 |
Cayman Chemical’s mission is to help make research possible by supplying scientists worldwide with the basic research tools necessary for advancing human and animal health. Our utmost commitment to healthcare researchers is to offer the highest quality products with an affordable pricing policy.
Our scientists are experts in the synthesis, purification, and characterization of biochemicals ranging from small drug-like heterocycles to complex biolipids, fatty acids, and many others. We are also highly skilled in all aspects of assay and antibody development, protein expression, crystallization, and structure determination.
Over the past thirty years, Cayman developed a deep knowledge base in lipid biochemistry, including research involving the arachidonic acid cascade, inositol phosphates, and cannabinoids. This knowledge enabled the production of reagents of exceptional quality for cancer, oxidative injury, epigenetics, neuroscience, inflammation, metabolism, and many additional lines of research.
Our organic and analytical chemists specialize in the rapid development of manufacturing processes and analytical methods to carry out clinical and commercial GMP-API production. Pre-clinical drug discovery efforts are currently underway in the areas of bone restoration and repair, muscular dystrophy, oncology, and inflammation. A separate group of Ph.D.-level scientists are dedicated to offering Hit-to-Lead Discovery and Profiling Services for epigenetic targets. Our knowledgeable chemists can be contracted to perform complete sample analysis for analytes measured by the majority of our assays. We also offer a wide range of analytical services using LC-MS/MS, HPLC, GC, and many other techniques.
Accreditations
ISO/IEC 17025:2005
ISO Guide 34:2009
Cayman is a leader in the field of emerging drugs of abuse, providing high-purity Schedule I-V Controlled Substances to federally-licensed laboratories and qualified academic research institutions for forensic analyses. We are certified by ACLASS Accreditation Services with dual accreditation to ISO/IEC 17025:2005 and ISO Guide 34:2009.
This mixture contains the characteristic metabolites of both PGI2 and TXA2. Contents: Thromboxane B2, 11-dehydro Thromboxane B2, 6-keto Prostaglandin F1?,...
Cytosolic PGE synthase (cPGES) is a glutathione-dependent enzyme with a predicted size of 18.6 kDa (23 kDa on SDS-PAGE). The...
CD34 is a transmembrane phosphoglycoprotein and sialomucin protein that is commonly used as a marker for hematopoietic progenitor cells.{59706,59704} It...
Headquarters:
Parc d’activités du Pas du Lac
10 bis avenue Ampère
78180 Montigny le Bretonneux
France
Copyright © 2024 BERTIN BIOREAGENT. All rights reserved | Terms & conditions
